F.D.A. Clears New Cancer-Fighting Drug From Roche

.

F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.


Latest News

Although Scientists say GMOs are Safe to Eat But it is Not Easy to Convince Ever
Central States Pension Fund has No New Recovery Plan Seeks Legislation to Protec
Does Fewer Opioid Prescriptions in the U.S Reflect a Curb in the Wave of Addicti
Japan’s Exports Drop further in April adding to a Gloomy Outlook
The Long Drawn Battle for Control Over Sumner Redstone’s Trust Takes New Turn
April Payrolls Reflect Significant Increases in Eleven US States
Bids for Yahoo may Not Match Earlier Expectations
Tribune Publishing and Garnet Company Carry on with Takeover Battle
Oregon Governor asks glass firm to halt production amid pollution concerns
G7 finance ministers to meet on Friday
Bayer AG makes unsolicited offer for Monsanto